Every material Form 8-K Monopar Therapeutics has filed with the SEC since June 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Monopar Therapeutics reported second quarter 2026 results with a net loss of $5.3 million, or $0.62 per share, up from $2.5 million, or $0.35 per share, a year earlier. The company said R&D spending rose as it prepares a potential ALXN1840 launch, and it reported $134.3 million in cash as of June 30, 2026.
Net loss was $5.3 million, or $0.62 per share, versus $2.5 million, or $0.35 per share, in Q2 2025.
R&D expenses were $4,766,832, up from $1,730,000, mainly due to a $2,026,851 increase in contractor and consulting costs.
Cash, cash equivalents and investments were $134.3 million at June 30, 2026, which the company says will support operations through at least December 31, 2027.
The company began a rolling NDA submission for ALXN1840 for Wilson disease on July 22, 2026, and expects to complete it within the next few months.
Monopar Therapeutics said it has begun a rolling submission of a New Drug Application to the FDA for ALXN1840 (tiomolibdate choline) for Wilson disease, and has submitted its first completed sections. The filing is a regulatory milestone; approval is not assured, and the company says the drug could receive a pediatric Priority Review Voucher if approved.
Monopar has initiated a rolling NDA submission for ALXN1840 with the FDA and has submitted the first completed sections.
The FDA authorized the rolling submission, which lets completed sections be reviewed while remaining sections are finalized.
ALXN1840 received Rare Pediatric Disease designation from the FDA in June 2026, which could allow a pediatric Priority Review Voucher at approval.
Monopar Therapeutics said the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline), its late-stage candidate for Wilson disease. The designation gives the company the potential to receive a pediatric Priority Review Voucher if the drug is approved, but the filing does not say whether approval will come or whether a voucher will be awarded.
FDA granted Rare Pediatric Disease designation to ALXN1840 for Wilson disease, announced June 30, 2026
The designation provides potential eligibility for a pediatric Priority Review Voucher at the time of NDA approval
The filing does not report revenue, earnings, or guidance
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Monopar Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →